A prognostic index predicting survival in transformed Waldenström macroglobulinemia.


Journal

Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435

Informations de publication

Date de publication:
01 11 2021
Historique:
aheadofprint: 12 11 2020
received: 10 06 2020
entrez: 12 11 2020
pubmed: 13 11 2020
medline: 28 5 2021
Statut: epublish

Résumé

Histological transformation into diffuse large B-cell lymphoma is a rare complication in patients with Waldenström macroglobulinemia (WM) usually associated with a poor prognosis. The objective of this study was to develop and validate a prognostic index for survival in transformed WM patients. Through this multicenter, international collaborative effort, we developed a scoring system based on data from 133 patients with transformed WM who were evaluated between 1995 and 2016 (training cohort). Univariate and multivariate analyses were used to propose a prognostic index with 2-year survival after transformation as an end-point. For external validation, a data set of 67 patients was used to evaluate the performance of the model (validation cohort). By multivariate analysis, three adverse covariates were identified as independent predictors of 2-year survival after transformation: elevated serum LDH (2 points), platelet count < 100 x 109/L (1 point) and any previous treatment for WM (1 point). Three risk groups were defined: low-risk (0-1 point, 24% of patients), intermediate-risk (2-3 points, 59%, hazard ratio (HR) = 3.4) and high-risk (4 points, 17%, HR = 7.5). Two-year survival rates were 81%, 47%, and 21%, respectively (P < 0.0001). This model appeared to be a better discriminant than the International Prognostic Index (IPI) and the revised IPI (R-IPI). We validated this model in an independent cohort. This easy-to-compute scoring index is a robust tool that may allow identification of groups of transformed WM patients with different outcomes and could be used for improving the development of risk-adapted treatment strategies.

Identifiants

pubmed: 33179472
doi: 10.3324/haematol.2020.262899
pmc: PMC8561274
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

2940-2946

Références

Clin Cancer Res. 2016 Jun 1;22(11):2755-64
pubmed: 26792260
Am J Hematol. 2016 Oct;91(10):1032-5
pubmed: 27415417
Am J Hematol. 2020 Mar;95(3):274-281
pubmed: 31814157
Blood. 2007 Mar 1;109(5):1857-61
pubmed: 17105812
J Clin Oncol. 2013 Jan 20;31(3):301-7
pubmed: 23233721
J Clin Oncol. 2000 Nov 15;18(22):3782-93
pubmed: 11078491
N Engl J Med. 2012 Aug 30;367(9):826-33
pubmed: 22931316
Clin Cancer Res. 2017 May 1;23(9):2232-2244
pubmed: 27923841
Leuk Lymphoma. 2020 Feb;61(2):465-468
pubmed: 31544563
Br J Haematol. 2019 May;185(4):767-770
pubmed: 30338525
Leukemia. 2019 Nov;33(11):2654-2661
pubmed: 31118465
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
J Clin Oncol. 2015 Sep 10;33(26):2863-9
pubmed: 26240224
Br J Haematol. 2017 Nov;179(3):439-448
pubmed: 28770576
Blood. 2013 Mar 14;121(11):2051-8
pubmed: 23321251
J Clin Oncol. 2006 May 20;24(15):2343-51
pubmed: 16710033
Semin Oncol. 2003 Apr;30(2):110-5
pubmed: 12720118
Blood. 2008 Jan 15;111(2):558-65
pubmed: 17962512
N Engl J Med. 2018 Apr 12;378(15):1396-1407
pubmed: 29641966
Blood. 2004 Sep 1;104(5):1258-65
pubmed: 15126323
Lancet Oncol. 2019 Jan;20(1):31-42
pubmed: 30518502
Stat Med. 1996 Feb 28;15(4):361-87
pubmed: 8668867
Br J Haematol. 2018 Feb;180(3):374-380
pubmed: 29181840
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Br J Haematol. 2017 Sep;178(5):699-708
pubmed: 28782811
Blood. 2018 Jun 21;131(25):2761-2772
pubmed: 29692342
J Clin Oncol. 2018 Oct 12;:JCO1800138
pubmed: 30312133
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
Blood. 2009 Apr 30;113(18):4163-70
pubmed: 19196866
Ann Hematol. 2017 Jan;96(1):1-8
pubmed: 27641425

Auteurs

Eric Durot (E)

Department of Hematology, University Hospital of Reims and UFR Médecine, Reims. edurot@chu-reims.fr.

Lukshe Kanagaratnam (L)

Department of Research and Innovation, University Hospital of Reims, Reims.

Saurabh Zanwar (S)

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.

Efstathios Kastritis (E)

Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens.

Shirley D'Sa (S)

University College London Hospitals (UCLH) NHS Foundation Trust, London.

Ramon Garcia-Sanz (R)

Department of Hematology, University Hospital of Salamanca, CIBERONC and Research Biomedical Institute of Salamanca (IBSAL), Salamanca.

Cécile Tomowiak (C)

Department of Hematology and CIC U1402, University Hospital of Poitiers, Poitiers.

Bénédicte Hivert (B)

Department of Hematology, Hospital of Lens, Lens.

Elise Toussaint (E)

Department of Hematology, University Hospital of Strasbourg, Strasbourg.

Caroline Protin (C)

Department of Hematology, IUCT Oncopole, Toulouse.

Jithma P Abeykoon (JP)

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.

Thomas Guerrero-Garcia (T)

Department of Hematology/Oncology, Delbert Day Cancer Institute, Rolla, MO.

Gilad Itchaki (G)

Institute of Hematology, Rabin Medical Center, Sackler Medical School, Tel-Aviv University, Israel.

Josephine M Vos (JM)

Amsterdam University Medical Center (UMC) and LYMMCARE, Amsterdam.

Anne-Sophie Michallet (AS)

Department of Hematology, Léon Bérard Center, Lyon.

Sophie Godet (S)

Department of Hematology, University Hospital of Reims and UFR Médecine, Reims.

Jehan Dupuis (J)

Lymphoid Malignancies Unit, Henri Mondor Hospital, Créteil.

Stéphane Leprêtre (S)

Inserm U1245 and Department of Hematology, Henri Becquerel Center and Normandie University UNIROUEN, Rouen.

Joshua Bomsztyk (J)

University College London Hospitals (UCLH) NHS Foundation Trust, London.

Pierre Morel (P)

Department of Hematology, University Hospital of Amiens, Amiens.

Véronique Leblond (V)

Department of Hematology, Pitié-Salpêtrière Hospital and Sorbonne University, UPMC Paris, GRECHY.

Steven P Treon (SP)

Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Meletios A Dimopoulos (MA)

Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens.

Prashant Kapoor (P)

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN.

Alain Delmer (A)

Department of Hematology, University Hospital of Reims and UFR Médecine, Reims.

Jorge J Castillo (JJ)

Bing Center for Waldenström Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH